Recon

DePuy Synthes ATTUNE® Knee Surpasses 1 Million Patients Implanted Worldwide

WARSAW, Ind., June 23, 2020 – Today, DePuy Synthes*, a Johnson & Johnson Medical Devices Company** announced that more than one million patients globally have been implanted with the ATTUNE® Knee. The milestone coincides with DePuy Synthes’ 125th anniversary this year and highlights  the company’s continued dedication to advance patient care in orthopaedics. Backed by comprehensive clinical and performance data (www.ATTUNEevidence.com), the ATTUNE Knee System is positioned for continued innovation through product development and digital surgery.

125 Years of Quality

Osteoarthritis (OA) is the most prevalent joint disease, affecting an estimated 250 million individuals worldwide,[i],[ii] with knee OA accounting for approximately 85% of the total disease burden.[iii],[iv] Studies have noted a direct correlation between knee OA – a leading source of chronic pain and disability – and quality of life, placing a substantial health care and socioeconomic burden on society.[v],[vi],[vii]

For 125 years, DePuy Synthes has been committed to improving patient outcomes and evolving to meet the next frontier of modern surgery.

“The ATTUNE Knee represents the largest research and development project in the history of DePuy Synthes,” said Rajit Kamal, Vice President and Global Franchise Leader, Knees, DePuy Synthes.*** “We continue to set a high bar for data-driven innovation in Total Knee Replacement (TKR) to improve patient satisfaction, while developing systems for the increasingly active and younger patient.”

One such individual, fifty-two year old bilateral ATTUNE Knee patient Renee Yahara, sought relief from her knee pain for many years.

“After a decade of knee pain in both knees and multiple failed attempts to find relief, I was discouraged, frustrated and struggled to find an option that worked for me. I talked to my doctor about the ATTUNE Knee, and we decided to replace both of my knees at once,” said Renee. “After surgery and physical therapy, I finally felt the pain relief I longed for after many years. The results surprised everyone including myself. I was back to work after a month, and now, I’m able to go dancing and clamming without hesitation.”

Bringing Innovation to the Forefront

As patient-centered care continues to drive medical innovation, patient-reported outcomes measures (PROMs) are important universal benchmarks to understand patients’ perceptions of their health and recovery, as well as the quality and satisfaction of care they receive. Interim results of two worldwide, multi-center prospective studies showed that the ATTUNE Knee System had significantly improved outcomes, compared to other leading knee systems, across a broad range of PROMs, including Quality of Life, Activities of Daily Living, Pain, Sports & Recreation at a minimum one-year follow up. Oxford Knee Scores (OKS) also reported significant improvements compared to baseline.[viii]

“The staying power of the ATTUNE Knee’s diverse portfolio goes hand-in-hand with the rapidly evolving knee OA landscape,” said Dr. Douglas Dennis, Orthopaedic Surgeon, Denver, CO.**** “The ATTUNE Knee System is designed to work in harmony with my patient’s native knee muscles and ligaments to increase stability and reduce pain. For my TKR patients, to be able to hear the positive impact it has had on their quality of life continues to be one of the most rewarding aspects of my career.”

The Future of TKA

By combining the latest in design, kinematics, engineering and materials, DePuy Synthes continues to expand the ATTUNE Knee platform to provide state-of-the-art knee solutions to meet the full spectrum of patient needs:

  • Launched in 2019, the ATTUNE Cementless Knee uses the same technologies of the ATTUNE Knee System and Rotating Platform option, with the added benefit of biologic fixation with POROCOAT™ Porous Coating.[ix] Also available in a hybrid construct which includes a cementless Femoral Component with a cemented Fixed Bearing or Rotating Platform Tibial base.
  • The ATTUNE S+™ Technology Tibial Base is designed to enhance tibial fixation with its innovative combination of macrolock features and a microblast surface finish on the tibial base.

Beyond implant technology and the surgical episode itself, DePuy Synthes is investing in innovations across the care continuum to further improve patient satisfaction and outcomes, working with hospitals and health systems to increase the value of TKR for patients and surgeons. This includes the introduction of VELYS™ Digital Surgery, a platform of connected technologies for orthopaedics that leverage data insights from pre-op through surgical planning, intra-op, and post-op to enhance the entire experience for patients, surgeons and healthcare systems.

For patient resources visit ATTUNEKnee.com and for more information on ATTUNE Knee System data, please visit ATTUNEevidence.com.

About Johnson & Johnson Medical Devices Companies

At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere. 

About DePuy Synthes

DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within the Johnson & Johnson’s Medical Devices segment.

***Rajit Kamal is employed by Medical Device Business Services, Inc.

****
Dr. Douglas Dennis is a surgeon innovator for DePuy Synthes Joint Reconstruction.


[i] Moskowitz, R.W., (2009). The burden of osteoarthritis: clinical and quality-of-life issues. The American Journal of Managed Care, 15(8 Suppl): S223-9, PMID:19817508, https://europepmc.org/abstract/med/19817508

[ii] Hunter, D,J., Bierma-Zeinstra S. Osteoarthritis. (2019). Lancet, 393 (10182): p1745-1759. DOI: https://doi.org/10.1016/S01406736(19)30417-9

[iii] Vos, T., et al. (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388(10053): 1545-602 https://doi.org/10.1016/S0140-6736(16)31678-6

[iv] Wallace, I.J., et al. (2017). Knee osteoarthritis has doubled in prevalence since the mid-20th century. PNAS. Vol. 114: 9332-9336

[v] Kawano, M.M., et al. (2015). Assessment of quality of life in patients with knee osteoarthritis. Acta Ortop Bras; 23(6): 307-10. doi:10.1590/1413-785220152306150596.PMID: 27057143; PMCID: PMC4775507

[vi] Abbott, J.H., et al. (2017). The quality-of-life burden of knee osteoarthritis in New Zealand adults: A model-based evaluation. PLoS ONE 12(10): e0185676. https://doi.org/10.1371/journal.pone.0185676

[vii] Losina, E., et al. (2011). Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med. 154(4):217-26. doi: 10.7326/0003-4819-154-4-201102150- 00001. PMID: 21320937; PMCID: PMC3260464

[viii] Hamilton, W.G., et al. Early Patient Reported Outcomes with New Primary Vs. Contemporary Total Knee Arthroplasty: A Comparison of Two, Worldwide, Multi-Center Prospective Studies. E-poster – ISTA 2016.

[ix] Napier RJ, et al. A prospective evaluation of a largely cementless total knee arthroplasty cohort without patellar resurfacing:10-year outcomes and survivorship. BMC Musculoskelet Disord, 2018. 19(1): p. 205.

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button
Close